abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 01일 18시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제118회 대한화학회 학술발표회, 총회 및 기기전시회 안내 Liporaxel® (DHP107), the first-generation oral paclitaxel delivery system

등록일
2016년 9월 2일 09시 41분 19초
접수번호
2500
발표코드
MAT1-5 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 15시 : 10분
발표형식
심포지엄
발표분야
재료화학 - Nanobio-materials for Biomedical Application
저자 및
공동저자
이인현
대화제약 판교연구소, Korea
The first successful oral paclitaxel formulation, Liporaxel® (DAEHWA Pharm. Co., DHP107), has been prepared by dissolving paclitaxel in the mixture of non-toxic lipid excipients and surfactants using DH-LASED® (Dae Hwa Lipid bAsed Self Emulsifying Drug delivery) technology. Unlike the conventional oral paclitaxel dosage forms under development, DHP107 was effectively absorbed in the intestinal tract without concurrent use of P-glycoprotein inhibitors such as cyclosporine A, SDZ PSC 833, and HM30171A. In a rodent xenograft preclinical cancer model, the bioavailability of Liporaxel® (DHP107) was about 50 % as compared to I.V. paclitaxel. Moreover, the preclinical trials of Liporaxel® (DHP107) showed excellent antitumor efficacy and demonstrated its safety in toxicology study. Subsequently, we successfully completed its clinical studies up to phase 3. The clinical studies of Liporaxel® (DHP107) re-confirmed its efficacy and safety in gastric cancer patients as compared to the I.V. paclitaxel. Overall, we believe that the Liporaxel® (DHP107) is able to improve therapeutic efficacy of the P.O. paclitaxel administration and further the quality of life of cancer patients and family.

상단으로